Sugi Predict
/ Targets
/ SLC75A1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to SLC75A1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Effect of Age on the Renal Clearance of Adefovir |
PHASE4 | WITHDRAWN |
| A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) |
PHASE2 | COMPLETED |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies |
PHASE1 | COMPLETED |
| THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC |
PHASE1 | COMPLETED |
| Effect of, OAT3, on the Renal Secretion of Cefotaxime |
PHASE1 | COMPLETED |
| Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters |
EARLY_PHASE1 | COMPLETED |
| Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer |
EARLY_PHASE1 | UNKNOWN |
| Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I |
EARLY_PHASE1 | COMPLETED |
| The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism |
EARLY_PHASE1 | UNKNOWN |
| Natural History Study of SLC25A46 Mutation-related Mitochondriopathy |
nan | COMPLETED |
| SLC13A5 Deficiency Natural History Study - Remote Only |
nan | ENROLLING_BY_INVITATION |
| Role of the ATP7A Transporter in Ovarian Cancer |
nan | COMPLETED |
| Impact of Genetics on Metformin Pharmacokinetics |
nan | COMPLETED |
| Bile Acid Effects in Fetal Arrhythmia Study |
nan | UNKNOWN |
| Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors |
nan | UNKNOWN |
| Oxalate and Citrate in Humans - Response to Citrate |
nan | RECRUITING |
| Individualized Antiretroviral Therapy |
nan | COMPLETED |
| Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise |
nan | COMPLETED |
| ADPKD Alterations in Hepatic Transporter Function |
nan | COMPLETED |
| Effect of Pharmacogenetics on Imatinib Plasma Level and Response |
nan | COMPLETED |
| Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs |
nan | COMPLETED |
| Genetically Guided Statin Therapy |
nan | COMPLETED |
| Epidemiology of Gout in French Polynesia |
nan | COMPLETED |
| Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients |
nan | UNKNOWN |
| Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides |
nan | COMPLETED |
| SLC6A1-NDD Prospective Longitudinal Natural History Study |
nan | NOT_YET_RECRUITING |
| Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient |
nan | UNKNOWN |
| Pharmacogenetics in Non Small Cell Lung Cancer |
nan | UNKNOWN |
| Genetic Variants and Iron Absorption |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a SLC75A1 binder may also engage these)